BRM412
Neovascular Eye Diseases (e.g., wet AMD)
PreclinicalActive
Key Facts
Indication
Neovascular Eye Diseases (e.g., wet AMD)
Phase
Preclinical
Status
Active
Company
About BRIM Biotechnology
Taiwanese biotech developing regenerative peptide therapies for ophthalmology and osteoarthritis using its PDSP platform.
View full company profile